Nycomed/Diatide Will Promote NeoTect As Less Invasive Than Lung Biopsy
Executive Summary
Nycomed Amersham and marketing partner Diatide will promote NeoTect as a less invasive means of distinguishing malignant from benign lung mass compared to needle biopsy and lung surgery, which are more painful and produce higher rates of complications compared to NeoTect, the companies said.
You may also be interested in...
Schering AG Enters Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
Schering AG hopes to accelerate its expansion into the radiopharmaceuticals market through a $128 mil. cash tender offer to acquire Diatide.
Schering AG Enters Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
Schering AG hopes to accelerate its expansion into the radiopharmaceuticals market through a $128 mil. cash tender offer to acquire Diatide.
WLF Decision Could Discourage Publishing Of Studies To Avoid Piggybacking
Manufacturers may be deterred from publishing their studies in order to avoid having the trials used by competitors following the July 28 federal court decision removing the prohibition on distributing off-label studies sponsored by competitors.